ライフサイエンスコーパス: gait speed

1 a 5-m walk time longer than 6 seconds (slow gait speed).

2 ociated with a 0.01 +/- 0.00-m/s decrease in gait speed.

3 cise resulted in the greatest improvement in gait speed.

4 body composition and age-related decline in gait speed.

5 sion scale) were also associated with slower gait speed.

6 scle area is also predictive of a decline in gait speed.

7 t and during gait, when they correlated with gait speed.

8 ss rest and gait, and did not correlate with gait speed.

9 A four-meter gait test was used to assess gait speed.

10 p time, stride length and time, cadence, and gait speed.

11 Frailty was assessed with the LFI and 4-m gait speed.

12 men, paralleling decreases in lean mass and gait speed.

13 ater VIIIa volume was associated with faster gait speed.

14 s often accompanied by slowed processing and gait speed.

15 neuropsychological test scores (NPZ-4), and gait speed.

16 nce of subjective memory complaints and slow gait speed.

17 associations of individual FES-I items with gait speed.

18 assessed by 10-time chair rise test and 4 m gait speed.

19 comes include the 1-year changes in SPPB and gait speed.

20 ate in the oldest age-quintile, but not with gait speed.

21 nd time, cadence, who could be classified by gait speed.

22 le's bodies and inferred their movements and gait speed.

23 uring treadmill walking are conserved across gait speed.

24 xhaustion, decreased grip strength, and slow gait speed.

25 ex, and hypertension significantly explained gait speed.

26 strumental activity of daily living, or slow gait speed.

27 exhaustion, low physical activity, and slow gait speed.

28 e was not associated with changes in aLM and gait speed.

29 ressive symptoms were associated with slower gait speed.

30 ts with depression has slowed processing and gait speeds.

31 LM (0.07 kg; 95% CI: 0.01, 0.14; P = 0.029), gait speed (0.05 m/s; 95% CI: 0.00, 0.11; P = 0.042), mu

32 (mean [SD], 6.91 [3.34] vs 7.21 [3.27]), and gait speed (0.79 [0.24] m/s vs 0.82 [0.23] m/s) than TM

33 ter adjustment for baseline characteristics, gait speed (0.80 +/- 0.27 vs. 0.96 +/- 0.23 m/s, p < 0.0

34 volume, and small-vessel disease but not on gait speed (0.85 vs 0.92 m/s, P = .01) or proportion of

35 le lowlanders walked on a treadmill at seven gait speeds (0.67-1.83 m s(-1)) on a level gradient unde

36 1.05 per 1-year increase [1.01-1.08]), lower gait speed (1.15 per 0.1-m/s slower gait [1.06-1.24]), l

37 or balance, 2.58 [95% CI, 1.62-4.12]; OR for gait speed, 2.11 [95% CI, 1.03-4.33]).

38 eline NM-MRI correlated with slower baseline gait speed (346 of 1807 substantia nigra-ventral tegment

39 The primary outcome measures were gait speed (6-minute walk), cardiovascular fitness (peak

40 whole cohort with physical performance [fast gait speed, 6 min walk test (6MWT), PROMIS score, and SF

41 sts such as total SPPB score, usual and fast gait speed, 6MWT, and SF36PFS raw score in the males, re

42 L-AABA was positively associated with usual gait speed, 6MWT, total SPPB score, and SF36PFS raw scor

43 CI], 5.2-23.9), 2.6 times the odds of a slow gait speed (95% CI, 1.4-4.8), and 3.2 times the odds of

44 morbidity (OR, 1.03 per 0.1-m/s decrease in gait speed; 95% CI, 1.00-1.05).

45 mortality (OR, 1.11 per 0.1-m/s decrease in gait speed; 95% CI, 1.07-1.16).

46 Associations of gait speed, activity fragmentation, and their interactio

47 monary function had significantly slower 4-m gait speed (all but one p < 0.05).

48 eedback and could not be explained by slower gait speed alone.

49 At-home gait speed also provides a more sensitive marker for tra

50 There was no association between gait speed and 2-back working memory performance in youn

51 sociation between continuous and categorical gait speed and 30-day all-cause mortality before and aft

52 the global and regional associations between gait speed and Abeta in the whole sample and the CN subs

53 there was a significant interaction between gait speed and activity fragmentation (HR, 0.92 [95% CI,

54 Initial assessment of gait speed and activity fragmentation occurred from Janu

55 A model with gait speed and all covariates had comparable predictive

56 changes in appendicular lean mass (aLM) and gait speed and also 6-y incidence of mobility limitation

57 king speeds, and the recovery of able-bodied gait speed and behavior from impaired gait is considered

58 n gait characteristics at normal and maximal gait speed and CaF in community-dwelling older adults.

59 nce had significant genetic correlation with gait speed and chair stand time (range |0.29-0.53|; all

60 pharmacy decreased exploration (reduced mean gait speed and climbing) during the habituation period,

61 Dual decline in gait speed and cognition has been found to be associated

62 d Cox proportional hazards models (including gait speed and daily walking time as measures of physica

63 The inverse association between gait speed and depressive symptoms appears to be bidirec

64 ments than MAT on some secondary measures of gait speed and fatigue.

65 ment or easily performed assessments such as gait speed and grip strength can be helpful to assess th

66 This study aimed to evaluate whether gait speed and grip strength predicted clinical outcomes

67 composite scores for constructs of impaired gait speed and grip strength.

68 Gait speed and handgrip strength were obtained, and pati

69 t mice treated with NIM-811 showed increased gait speed and improved Tarlov scores compared to vehicl

70 atiotemporal asymmetries depends on both the gait speed and level of weakness.

71 Gait speed and mobility were significantly improved in t

72 Several regional associations between gait speed and PiB uptake withstood relevant adjustments

73 years, polypharmacy was associated with slow gait speed and recurrent falls, even after accounting fo

74 Primary outcome of gait speed and secondary outcomes representing component

75 receiver operating characteristic analysis, gait speed and TUAG more strongly predicted 3-year morta

76 FES-I increasing to 29.2% by adding maximum gait speed and walk ratio.

77 subregion volume in the correlation between gait speed and working memory in healthy younger adults.

78 The relationship between gait speed and working memory is well-understood in olde

79 ar volumes are distinctively associated with gait speed and working memory performance in healthy you

80 mine if there is: (1) an association between gait speed and working memory performance; and (2) a med

81 mechanism underlying the association between gait speed and working memory.

82 ary study outcomes were changes in mobility (gait speed) and accrual of white matter hyperintensity v

83 l [CI], 0.30 to 0.59, per 1m/sec increase in gait speed) and the two-year lagged association fully (O

84 ysical frailty (defined on the basis of slow gait speed) and were followed up with monthly telephone

85 tivity level, weakness, exhaustion, and slow gait speed), and incident CVD as onset of coronary arter

86 found 9.7% lower grip strength, 9.9% slower gait speed, and 13.9% slower timed up-and-go time than w

87 tions suggested that cadence-based measures, gait speed, and ambulation-related signal perturbations

88 al included step regularity, sample entropy, gait speed, and amplitude dominant frequency, among othe

89 Short Form SF-12, repeated chair rise, 20-m gait speed, and Center for Epidemiological Studies Depre

90 ess and a score for each component (balance, gait speed, and chair stands) of 2 or less indicated poo

91 Patients' clinical characteristics, usual gait speed, and Five Times Sit to Stand Test time were c

92 health as measured by frailty index scores, gait speed, and glucose and insulin tolerance tests.

93 es, pacemaker use, atrial fibrillation, slow gait speed, and nonfemoral access were significantly ass

94 anges in physical capability (grip strength, gait speed, and physical activity), sensory function (si

95 cs, cardiovascular risk factors, depression, gait speed, and physical activity.

96 dopamine availability, increased processing/gait speed, and relieved depressive symptoms.

97 tcomes (four-step stair climbing time, usual gait speed, and time to rise five times from a chair wit

98 frequent rests among older adults with slow gait speed are associated with lower risk of future MCI/

99 Gait variables, especially gait speed, are strongly associated with CaF.

100 Our findings indicate that declines in gait speed as a function of age and frailty are associat

101 These can be supplemented with gait speed as a measure of frailty.

102 e findings reinforce the clinical utility of gait speed as a measure of risk and a potential target f

103 After adjustment, each 0.1-m/s decrement in gait speed associated with a 26% higher risk for death,

104 (p-values both < 0.001) included daily peak gait speed averaged over the preceding 30 days (r = 0.63

105 pt for vitamin C were associated with faster gait speed [B (SE) per 10-mg higher intake/d, range: 0.0

106 IS-SF20a) and physical performance measures (gait speed, balance, lower body strength, grip strength,

107 utcome (OR: 3.17, 95% CI: 1.28-8.22), slower gait speed (beta: 0.13, 95% CI: 0.01-0.25), and recurren

108 dwelling older adults (aged >=65 years) with gait speed between 0.60 and 1.20 m/s.

109 The greatest difference in gait speed between motion capture and OpenPose was less

110 measures of biological aging: pace of aging, gait speed, brain age (specifically, BrainAGE score), an

111 sorders) and outcome measure (pace of aging, gait speed, brain age, and facial age).

112 ; individuals in the standard group improved gait speed by 0.081 (0.124) m/s over 12 weeks, 0.051 (0.

113 Gait speed, cadence, and step and stride durations and l

114 As the number of researchers increased, gait speed, cadence, and stride length increased, and st

115 VPA) and post-hoc seed-to-voxel analyses for gait speed, cadence, double support time, stride length,

116 Gait speed can be used to refine estimates of operative

117 omized clinical trial found no difference in gait speed change between the standard and standard-plus

118 Gait speed changes were consistent with reported changes

119 Gait speed, cognitive index, conventional MRI markers of

120 d including age, sex, vascular risk factors, gait speed, cognitive index, MRI, and diffusion measures

121 After HDBI polypharmacy, mean gait speed consistently decreased throughout the experim

122 tion of short-latency afferent inhibition to gait speed, controlling for age, posture and gait sympto

123 Each 0.2-m/s decrease in gait speed corresponded to an 11% increase in 30-day mor

124 adults aged 65 years or older with baseline gait speed data, followed up for 6 to 21 years.

125 lly in black women, but not over 6 y or with gait speed decline.

126 thigh intermuscular fat predicted the annual gait-speed decline (+/-SE) in both men and women (-0.01

127 nly body-composition measures that predicted gait-speed decline in men and women combined.

128 ntermuscular fat are important predictors of gait-speed decline, implying that fat infiltration into

129 tle research has identified risk factors for gait-speed decline.

130 Gait speed declined by 0.06 +/- 0.00 m/s over the 4-y pe

131 res (>80th percentile) were more impaired by gait speed, difficulty with Instrumental Activities of D

132 -Blood pressure, gait speed, digit symbol substitution test, and the Cent

133 exercise on any measures of muscle strength, gait speed, dynamic balance, reaction time, or blood lip

134 core effect size = 0.41, p = .001; dual-task gait speed effect size = 0.43, p = .002).

135 red on a scale from 0 to 5 by grip strength, gait speed, exhaustion, shrinkage, and physical activity

136 ition was an independent predictor of slower gait speed, explaining 37% of variability.

137 ification of frail patients with the slowest gait speeds facilitates preprocedural evaluation and ant

138 ith a four-part battery of LEF tasks: normal gait speed, fastest-comfortable gait speed, isometric le

139 Gait speed for 6 m and activity fragmentation assessed b

140 d side ([Formula: see text] = 0.029), faster gait speed ([Formula: see text] = 0.018) and lower IADL

141 In an exploratory analysis, gait speed from both modalities significantly related to

142 Time to complete 10 chair rises, 4-m gait speed, grip strength, and a modified short physical

143 Function was measured in the physical [gait speed, grip strength, chair stand] and cognitive [d

144 predictive scale in each domain was: 5-meter gait speed >/=6 seconds as a measure of frailty (odds ra

145 Physical frailty (defined as gait speed >10 seconds on the rapid gait test) was asses

146 n upper-limb impairment, arm motor function, gait speed, hand function, and physical and functional l

147 climbing test, 6-min walking distance, fast gait speed, hand grip strength, and isometric leg extens

148 -step tests), chair rise with arms, and fast gait speed improved significantly from baseline to week

149 of SVD-related morphologic brain changes on gait speed in addition to age, sex and hypertension inde

150 with annualized change in grip strength and gait speed in adults from the Framingham Offspring study

151 These findings support the inclusion of gait speed in dementia risk screening assessments.

152 r coupling in the middle cerebral artery and gait speed in elderly individuals with impaired cerebral

153 To examine the association between Abeta and gait speed in elderly individuals without dementia and t

154 ther amyloid-beta (Abeta) is associated with gait speed in elderly individuals without dementia and w

155 influence the association between Abeta and gait speed in elderly individuals without dementia.

156 l Abeta deposition is associated with slower gait speed in elderly individuals without dementia; howe

157 y mechanisms responsible for preservation of gait speed in elderly people with cerebrovascular diseas

158 of dopamine, L-DOPA improved processing and gait speed in older adults with depression and significa

159 e that NM-MRI is sensitive to variability in gait speed in patients with LLD, suggesting this non-inv

160 bolic shift may contribute to NCI and slowed gait speed in PWH.

161 al significant and independent predictors of gait speed in the regression model.

162 ed with increase in grip strength and faster gait speed in this cohort of adults.

163 m/s; men <0.825 m/s) and secondary outcomes (gait speed, incident self-reported mobility, and stair c

164 was accompanied by significant increases in gait speed, incline on the treadmill, the maximal volunt

165 Gait speed increased by .03 m/s from the no research gro

166 nee strength, power, and quality and the 4-m gait speed increased similarly in both groups.

167 For gait speed, individuals in the standard-plus group had a

168 orporating a single-leg stance partition and gait speed information.

169 Functional status was assessed by gait speed, instrumental activities of daily living (IAD

170 The 4-m gait speed is a reliable, valid, and responsive measure

171 In summary, gait speed is an easily obtained "vital sign" that accur

172 Gait speed is an independent predictor of adverse outcom

173 In older adults, every 0.1-m/s slower gait speed is associated with a 12% higher mortality.

174 toms and physical performance measured using gait speed is bidirectional.

175 Gait speed is independently associated with 30-day morta

176 asks: normal gait speed, fastest-comfortable gait speed, isometric leg strength, and timed up-and-go.

177 r year, have concerns about falling, or have gait speed less than 0.8 to 1 m/s should receive fall pr

178 iption medications, excluding ART) with slow gait speed (less than 1 meter/second) and falls, includi

179 tween participants' self-perceived different gait speed levels, and effects of different floor surfac

180 lf-reported pain intensity, quality of life, gait speed, lower body muscle strength, lower body flexi

181 prediction of mortality, an older age, lower gait speed, lower gray matter volume, and greater global

182 Poor performance was defined as a gait speed <1 m/s after 9 y of follow-up (n = 1542).

183 The prevalence of slow gait speed (<1 m/sec) decreased from 63% to 46% (P = .02

184 change in grip strength (kg/y) and change in gait speed (m/s/y) over the follow-up period were used.

185 n models to analyse repeated measurements of gait speed (m/sec) and elevated depressive symptoms (def

186 ction between cognitive task performance and gait speed may differ according to walking intensity.

187 mental activities of daily living (IADL) and gait speed, may be an important pretransplant assessment

188 rence, 0.068 [95% CI, -0.076 to 0.212]), and gait speed (mean [SD], -0.0160 [0.148] m/s vs -0.007 [0.

189 Gait speed, measured at 0, 2, 4, and 6 years and trial c

190 We collected over 200,000 gait speed measurements.

191 nd post-L-DOPA differences in processing and gait speed measures, depressive symptoms, and reported s

192 r values indicating better performance), and gait speed (meters per second) were measured.

193 Physical performance measures, such as gait speed, might help account for variability, allowing

194 The estimated 4-m gait speed minimal important difference was 0.03-0.06 m/

195 the 3 components of sarcopenia, only slower gait speed (muscle performance) was independently associ

196 Therefore, exercise can improve gait speed, muscle strength, and fitness for patients wi

197 ry outcomes: grip strength (n = 2452) and/or gait speed (n = 2422) measured over 3 subsequent examina

198 Secondary outcome measures were gait speed, number of falls, daily activity (Barthel ind

199 with polypharmacy had a higher risk of slow gait speed (odds ratio [OR] = 1.78; 95% confidence inter

200 Gait decline was defined as a decline in gait speed of 0.05 m/s or greater per year across the st

201 women; and 79.8%, white; and had a mean (SD) gait speed of 0.92 (0.27) m/s.

202 m least active to most active had an average gait speed of 4.0, 4.2, 4.3, and 4.5 feet/second, respec

203 ed mean differences (MDs) in change rates in gait speed or grip strength between anticholinergic TSDD

204 have significantly different improvements in gait speed or secondary outcomes representing the compon

205 mpound B (PiB) positron emission tomography, gait speed over 4.57 m (15 ft), and cognition on the Min

206 (P = .01), and 0.02 m/s slower time-updated gait speed (P < .0001).

207 CI, 0.17 SD lower NPZ-4, and 0.04 m/s slower gait speed (P .01 for each).

208 arkinson's disease had significantly reduced gait speed (P = 0.002), stride length (P = 0.008) and st

209 (p = 0.03), exhaustion (p = 0.01), and slow gait speed (p = 0.03) were significantly associated with

210 wing measured by the Digit Symbol test and a gait speed paradigm.

211 djustment for covariates (including previous gait speed) partially explained both the concurrent (bet

212 ried index, incorporating handgrip strength, gait speed, physical activity, unintended weight loss, a

213 line NM-MRI and treatment-related changes in gait speed, processing speed, or depression severity (al

214 needed to complete the Timed Up and Go test, gait speed, pure-tone auditory detection thresholds, spe

215 vents, training adherence, balance measures, gait speed, quality of life, fatigue, and fitness levels

216 ted with LFI ( r = -0.54, P < 0.001) and 4-m gait speed ( r = 0.48, P < 0.001).

217 edicted 10-year survival across the range of gait speeds ranged from 19% to 87% in men and from 35% t

218 isk of mortality and the surgical procedure, gait speed remained independently predictive of operativ

219 22 and 12 metabolites for grip strength and gait speed, respectively.

220 re significantly associated with the 4-meter gait speed (rs928874, p = 5.61 x 10(-8); rs1788355, p =

221 age (P 0.49) in the LP females and (3) with gait speed (S 0.20) in the 120 participants.

222 rs) with 8.2 (5.4) years of follow-up in the gait speed sample, and 4200 participants (2458 [58.5%] w

223 ong the physical domains of pre-frailty, low gait speed seems to be the best predictor of future CVD.

224 esis can account for a portion of the slower gait speed seen in people with hemiparesis.

225 continuous variable based on grip strength, gait speed, serum albumin, and activities of daily livin

226 significant associations were found between gait speed, short-latency afferent inhibition, age and p

227 PwMS exhibited slower gait speed, shorter stride length, and impaired 360 degr

228 Chair rise and gait speed showed nonsignificant improvements of 1.27 se

229 Gait speed showed the largest percentage change among te

230 Furthermore, 4-m gait speed significantly predicted future hospitalizatio

231 onal analysis of the data shows that at-home gait speed strongly correlates with gold-standard PD ass

232 Compared with patients in the fastest gait speed tertile (>1.00 m/s), operative mortality was

233 ions for clinical studies evaluating the 4-m gait speed test in acute respiratory distress syndrome s

234 The 5-m gait speed test was performed in 15171 patients aged 60

235 , -1.7 to 5.0); and the median speeds on the gait-speed test were 1.03 m per second and 1.10 m per se

236 imensions (SF-6D), Timed Up and Go, and Fast Gait Speed tests.

237 inal measures of neurocognitive function and gait speed that are age-dependent, supporting the import

238 inically small, improvements in mobility and gait speed that are not sustained after treatment ends.

239 We compared handgrip strength, usual gait speed, timed up and go (TUAG), and 6-minute walking

240 Adding gait speed to a model that included estimated GFR signif

241 Addition of gait speed to the Society of Thoracic Surgeons predicted

242 ntegrating a measure of frailty, such as 5-m gait speed, to better capture the heterogeneity of the o

243 The overall median gait speed was 0.63 m/s (25th-75th percentile, 0.47-0.79

244 kg (males) and 20 (8.4) kg (females); median gait speed was 0.82 (0.34) m/s.

245 ean (SD) age was 77.4 (6.6) years; mean (SD) gait speed was 1.07 (0.16) m/s; and 244 (98.0%) complete

246 Gait speed was 2.6 m/min (0.30-4.95) higher in the treat

247 Further, the monitored gait speed was able to capture symptom fluctuations in r

248 Gait speed was also predictive of the composite outcome

249 Predicted survival based on age, sex, and gait speed was as accurate as predicted based on age, se

250 Four-meter gait speed was assessed at 6- and 12-month follow-up (AR

251 Relative gait speed was assessed with trunk accelerometry.

252 fragmentation (-1 SD), each 0.05-m/s slower gait speed was associated with a 19% increase in hazard

253 Slower gait speed was associated with elevated depressive sympt

254 gressiveness/type, every 0.1-m/s decrease in gait speed was associated with higher mortality (HR, 1.2

255 Among frailty components, slow gait speed was associated with incident DM and borderlin

256 Gait speed was associated with survival in all studies (

257 of individual data from 9 selected cohorts, gait speed was associated with survival in older adults.

258 red with nonusers, a greater decline rate in gait speed was found for those with 10-year TSDD 1096 or

259 Gait speed was measured using the 10-meter walk test, en

260 as at higher activity fragmentation (+1 SD), gait speed was not associated with MCI/AD (HR, 1.01 [95%

261 sarcopenia and body composition phenotyping, gait speed was the only sarcopenia measure associated wi

262 minimal clinical important change (MCIC) for gait speed was used to determine the changes and to clas

263 higher during the early postoperative phase (gait speed week 3 2.57 +/- 0.49 km/h vs. 2.16 +/- 0.70 k

264 aLM and gait speed were measured at baseline and at 3 and 6 y.

265 Cognitive task score and gait speed were measured.

266 Changes in gait speed were not different between treatment groups (

267 , dose-dependent increases in processing and gait speed were observed with L-DOPA (450-mg dose: proce

268 ociated with a 0.01 +/- 0.00-m/s decrease in gait speed, whereas every 16.92-cm(2) decrease in thigh

269 ores do not include frailty assessments (eg, gait speed), which are of particular importance for pati

270 d time, stride length and time, cadence, and gait speed while non-responders did not.

271 ains examined, the combination of decline in gait speed with memory had the strongest association wit

272 final model explained 72% of variability in gait speed with only short-latency afferent inhibition a

273 We assessed the association of 5-m gait speed with outcomes in a cohort of 8039 patients wh

274 Survival increased across the full range of gait speeds, with significant increments per 0.1 m/s.